The European Falsified Medicines Directive (FMD) comes into effect in February 2019 in order to tackle counterfeiting in the pharmaceutical industry, an issue the World Health Organisation (WHO) estimates affects up to one in ten medicines in poorer countries.

To date we have equipped nine of our facilities with serialisation capabilities and our plan is to ensure that 75 production lines across Europe are serialisation compliant.

As well as this being a problem regarding the safety of medicines, it is also a financial issue, costing around $30billion a year. The FMD will ensure complete traceability of all medicines, however for ,pharmaceutical companies and contract manufacturing organisations (CMOs), reaching compliance could be a challenge.

Waqas Qureshi interviews our Director Corporate Projects, Staffan Widengren, for an article in Packaging News on the issues presented by new track and trace regulations being rolled out across Europe.

Read the full article here:

Dispensing traceability over the counter